Vis enkel innførsel

dc.contributor.authorBerg, Lars Martin
dc.contributor.authorAnkjell, Torun Karina Solheim
dc.contributor.authorSun, Yi-Qian
dc.contributor.authorTrovik, Tordis A
dc.contributor.authorRikardsen, Oddveig G
dc.contributor.authorSjögren, Anders
dc.contributor.authorMoen, Ketil
dc.contributor.authorHellem, Sølve
dc.contributor.authorBugten, Vegard
dc.date.accessioned2021-03-04T08:35:12Z
dc.date.available2021-03-04T08:35:12Z
dc.date.created2020-07-06T10:38:35Z
dc.date.issued2020
dc.PublishedInternational Journal of Otolaryngology. 2020, .
dc.identifier.issn1687-9201
dc.identifier.urihttps://hdl.handle.net/11250/2731559
dc.description.abstractIn this randomized controlled trial, patients with non-severe obstructive sleep apnea (OSA) were treated with continuous positive airway pressure (CPAP) or a twin block mandibular advancement splint (MAS). The primary objective was to compare how CPAP and MAS treatments change the health-related quality of life (HRQoL) and self-reported sleep quality of patients after 12 months of treatment. In total, 104 patients were recruited: 55 were allocated to the CPAP-treatment group and 49 to the MAS-treatment group. We used the SF36 questionnaire to evaluate HRQoL and the Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep quality. All patients were included in the intention-to-treat analyses. These analyses showed improvements in the SF36 physical component score (from 48.8 ± 7.6 at baseline to 50.5 ± 8.0 at follow-up, p = 0.03) in the CPAP treatment group and in the mental component score (from 44.9 ± 12.1 to 49.3 ± 9.2, p = 0.009) in the MAS treatment group. The PSQI global score improved in both the CPAP (from 7.7 ± 3.5 to 6.6 ± 2.9, p = 0.006) and the MAS (8.0 ± 3.1 to 6.1 ± 2.6, p < 0.001) treatment group. No difference was found between treatment groups in any of the SF36 scores or PSQI global score at the final follow-up (p > 0.05) in any analysis. The improvement in the SF36 vitality domain moderately correlated to the improvement in the PSQI global score in both groups (CPAP: |r| = 0.47, p < 0.001; MAS: |r| = 0.36, p = 0.01). In the MAS treatment group, we also found a weak correlation between improvements in the SF36 mental component score and PSQI global score (|r| = 0.28, p = 0.05). In conclusion, CPAP and MAS treatments lead to similar improvements in the HRQoL and self-reported sleep quality in non-severe OSA. Improvements in aspects of HRQoL seems to be moderately correlated to the self-reported sleep quality in both CPAP and MAS treatments.en_US
dc.language.isoengen_US
dc.publisherHindawien_US
dc.relation.urihttps://doi.org/10.1155/2020/2856460
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectSøvnforstyrrelser / søvnproblemer / søvnbesværen_US
dc.subjectSleep Disordersen_US
dc.titleHealth-Related Quality of Life and Sleep Quality after 12 Months of Treatment in Nonsevere Obstructive Sleep Apnea: A Randomized Clinical Trial with Continuous Positive Airway Pressure and Mandibular Advancement Splintsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2020 Lars M. Berg et al.en_US
dc.source.articlenumber2856460en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1155/2020/2856460
dc.identifier.cristin1818683
dc.source.journalInternational Journal of Otolaryngologyen_US
dc.subject.nsiVDP::Otorhinolaryngologi: 755en_US
dc.subject.nsiVDP::Otolaryngology: 755en_US
dc.identifier.citationInternational Journal of Otolaryngology. 2020, 2856460.en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal